The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients

NCT02711410 · clinicaltrials.gov ↗

COMPLETED

Status

518

Enrollment

OTHER

Sponsor class

Conditions

Platelet Aggregation Inhibitors

Interventions

DRUG: Clopidogrel

Sponsor

National Cerebral and Cardiovascular Center, Japan